Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

• Market Cap: ₹16.00B
• Dividend Yield: 0.83%
• Average Volume (3M): 45.70K
• Price to Earnings (P/E): 26.2
• Beta (1Y): 1.16
• Revenue Growth: 34.72%
• EPS Growth: 196.94%
• Country: IN
• Employees: 1,025
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.62
• Shares Outstanding: 66,631,256
• 10 Day Avg. Volume: 11,523
• 30 Day Avg. Volume: 45,703
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹262.00
• Price Target Upside: 9.08% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: ₹262.00 ▲(9.08% Upside)

Jagsonpal Pharmaceuticals Ltd. demonstrates strong financial health, which is the most significant factor in its overall score. However, the technical indicators suggest bearish momentum, and the valuation is moderate, which tempers the overall score. The absence of earnings call insights and corporate events means these factors do not influence the score.

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) is a leading pharmaceutical company based in India, specializing in the production and distribution of a wide range of pharmaceutical products. The company focuses on the development of specialty and high-growth therapeutic areas, including gynecology, orthopedics, and other specialty segments. Jagsonpal Pharmaceuticals is committed to providing high-quality and affordable healthcare solutions to its customers both domestically and internationally.

How the Company Makes Money

Jagsonpal Pharmaceuticals Ltd. primarily generates revenue through the sale of its pharmaceutical products. The company manufactures and markets a variety of branded and generic formulations, catering to different therapeutic areas. Its revenue streams include domestic sales within India, which form a significant portion of its income, as well as international sales through exports. Key revenue drivers include its focus on specialty segments such as gynecology and orthopedics, which are high-demand areas in the pharmaceutical market. Additionally, partnerships with healthcare professionals, distributors, and strategic alliances play a critical role in expanding its market reach and enhancing its revenue-generating capabilities.

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Jagsonpal Pharmaceuticals Ltd. exhibits strong financial performance with robust revenue growth, healthy profit margins, and a solid balance sheet characterized by low leverage. Cash flow generation is positive, supporting reinvestment and dividends, though there is some variability in free cash flow growth.

Income Statement

Jagsonpal Pharmaceuticals Ltd. has demonstrated strong revenue growth over the years, with a notable increase in net income as well. Gross profit margin and net profit margin are healthy, indicating efficient cost management and profitability. The increase in EBIT and EBITDA margins further underscores the company's operational efficiency. Overall, the income statement reflects a robust and growing financial performance.

Balance Sheet

The company's balance sheet is solid, characterized by a strong equity base and a low debt-to-equity ratio, indicating low leverage and financial stability. The equity ratio is high, showcasing a strong asset base funded by equity rather than debt. This structure mitigates financial risk and provides a foundation for sustainable growth. However, the decline in cash and short-term investments over time could be a point of concern for liquidity management.

Cash Flow

Cash flow analysis shows a positive trajectory in operating cash flow and free cash flow, which supports the company's capacity to reinvest and pay dividends. The operating cash flow to net income ratio is strong, highlighting effective conversion of earnings into cash. However, the free cash flow growth rate has shown some variability, which could indicate fluctuations in capital expenditures or cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.69B	2.69B	2.09B	2.26B	2.37B	1.88B
Gross Profit	1.32B	1.72B	652.59M	1.30B	1.44B	1.07B
EBITDA	761.18M	510.71M	323.46M	284.53M	363.96M	234.72M
Net Income	553.61M	553.61M	224.63M	188.55M	267.21M	170.58M
Balance Sheet
Total Assets	2.78B	2.78B	2.17B	1.68B	1.95B	1.64B
Cash, Cash Equivalents and Short-Term Investments	1.29B	1.29B	1.48B	472.77M	1.15B	618.82M
Total Debt	92.39M	92.39M	89.41M	0.00	60.01M	67.88M
Total Liabilities	383.10M	383.10M	296.76M	375.99M	360.56M	422.73M
Stockholders Equity	2.40B	2.40B	1.87B	1.31B	1.59B	1.22B
Cash Flow
Free Cash Flow	0.00	549.52M	349.18M	51.31M	463.37M	277.53M
Operating Cash Flow	0.00	553.00M	351.66M	55.98M	466.54M	282.22M
Investing Cash Flow	0.00	-451.47M	-245.48M	-262.08M	-576.71M	-22.64M
Financing Cash Flow	0.00	-116.98M	-89.11M	-123.04M	-4.57M	-68.28M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 240.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Neutral. The current price of 240.2 is below the 20-day moving average (MA) of 244.50, below the 50-day MA of 248.45, and above the 200-day MA of 237.56, indicating a neutral trend. The MACD of -3.74 indicates Positive momentum. The RSI at 45.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HESTERBIO	68 Neutral	₹18.09B	48.11		0.33%	4.68%	94.22%
JAGSNPHARM	66 Neutral	₹16.00B	26.21		0.83%	34.72%	196.94%
BLISSGVS	63 Neutral	₹16.47B	15.41		0.32%	4.93%	29.92%
THEMISMED	56 Neutral	₹9.25B	33.15		0.50%	-6.86%	-118.14%
BAJAJHCARE	52 Neutral	₹13.62B	30.03		0.23%	17.50%	―
Sector *	51 Neutral	$7.95B	-0.40	-42.50%	2.21%	22.29%	-1.85%
LINCOLN	―	₹11.18B	12.95		0.32%	―	―